12:00 AM
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Squalamine: Phase I

Interim data from 39 patients in two Phase I dose-escalation studies showed that squalamine was well tolerated. MAGN expects to begin...

Read the full 85 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >